LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve ... defined as patients achieving at least a 50% reduction in apnea-hypopnea index (AHI), resulting in an AHI below 20.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback